Uncategorized Archives - Page 35 of 134

TuesdaySep 20, 2022 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere In September 2022, the company announced it was granted a patent for its 12-lead ECG Patch Monitor, opening a pathway to ischemia and arrhythmia detection innovation in ECG Patch products In August 2022, the company announced it was seeking FDA approval for its HeartBeam AIMI platform technology used to detect and diagnose heart attacks On November 15, 2021, HeartBeam had its IPO on the Nasdaq under ticker symbol ‘BEAT’ The company’s management team has significant experience in software…

MondaySep 19, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each year The current standard of care for GBM is ineffective for approximately 60% of patients Initial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present and two experiencing significant tumor reduction of up to 80% CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, recently participated in the…

ThursdaySep 15, 2022 9:00 am

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs The company is currently developing a treatment for concussion, a condition that currently does not have an FDA-approved treatment despite having both short- and long-term consequences Through animal studies, Odyssey has so far evidenced that PRV-002 can easily cross the blood-brain barrier to rapidly eliminate the swelling, oxidative stress, and inflammation in the brain caused by concussion while simultaneously restoring proper blood flow Odyssey is currently undertaking Phase 1 clinical studies with plans underway to commence its Phase 2 trial…

TuesdaySep 13, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials

U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomas Glioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosis CNS’s efforts to fill an unmet medical need arise from promise shown during Berubicin’s initial development by another company over 15 years ago, which included a small-scale human safety trial that produced a patient with no detectable cancer and others that saw tumor shrinkage and…

MondaySep 12, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Planning Phase 2 Trials of PRV-002 for Unmet Medical Needs in Concussion Therapies

Medical costs for concussions total $20 billion in the United States, a need for which there is no FDA-approved treatment The CDC estimates that more than 50% of people suffering a traumatic brain injury become moderately or severely disabled and have shorter life spans Odyssey provides a portfolio of diverse technologies and related medical products to meet the unmet medical needs of concussion and TBI patients Each year, medical costs in the United States for concussions total $20 billion ($400 billion worldwide). There is a significant unmet medical need for treatments for concussions in the medical landscape, with most diagnosed…

FridaySep 09, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumors Glioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cure CNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, Berubicin Berubicin is an anthracycline (chemotherapy agent) with the apparent ability to cross the blood-brain barrier to attack central nervous system tumors, which grants it a unique status among anthracyclines CNS has shown evidence…

WednesdaySep 07, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage

Medical company Odyssey Health has received approval from the Safety Review Committee to start Cohort II of its Phase I trial’s Multiday Ascending Dosing (“MAD”) stage The approval follows evidence that Odyssey’s PRV-002 concussion drug candidate was safe and well-tolerated, as seen in Cohort I of the MAD stage The pharmacokinetic analysis also supports the hypothesis that more drug is getting to the brain itself, backing the company’s use of its patent-pending breath-propelled intranasal drug administration device The company believes that the intranasal drug/delivery combination will be instrumental in the success of the PRV-002 drug candidate in planned Phase II/III…

WednesdaySep 07, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin

CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 million The company closed the quarter with $9.0 million in cash, and a working capital of approximately $10.3 million which, it is confident, will fund its operations into the 2023 calendar year CNS looks to continue site initiations across the U.S., Italy, France, Spain, and Switzerland, while also pushing for regulatory and ethics…

ThursdaySep 01, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research

When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”) So far, CNS has received FDA Fast Track Designation on its Berubicin clinical study, inching the company closer to offering a viable solution to the millions of people dealing with GBM, a devastating malignant brain cancer It remains committed to pushing the envelope in terms of research and development of potential GBM treatment, as we ll as brain cancers in general, to offer a viable solution to…

WednesdayAug 31, 2022 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials

Odyssey Health, Inc. (ODYY) Planning Phase 2 Trials of PRV-002 for Unmet Medical Needs in Concussion Therapies

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search